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erIntroduction: The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides
mammograms and diagnostic services for low-income, uninsuredwomen aged 40–64 years.Mammography
facilities within the NBCCEDP gradually shifted from plain-ﬁlm to digital mammography. The purpose of
this study is to assess the impact of replacing ﬁlm with digital mammography on health effects (deaths
averted, life-years gained [LYG]); costs (for screening and diagnostics); and number of women reached.
Methods: NBCCEDP 2010 data and data representative of the program’s target population were
used in two established microsimulation models. Models simulated observed screening behavior
including different screening intervals (annual, biennial, irregular) and starting ages (40, 50 years)
for white, black, and Hispanic women. Model runs were performed in 2012.
Results: The models predicted 8.0–8.3 LYG per 1,000 ﬁlm screens for black women, 5.9–7.5 for
white women, and 4.0–4.5 for Hispanic women. For all race/ethnicity groups, digital mammography
had more LYG than ﬁlm mammography (2%–4%), but had higher costs (34%–35%). Assuming a
ﬁxed budget, 25%–26% fewer women could be served, resulting in 22%–24% fewer LYG if all
mammograms were converted to digital. The loss in LYG could be reversed to an 8%–13% increase
by only including biennial screening.
Conclusions: Digital could result in slightly more LYG than ﬁlm mammography. However, with a
ﬁxed budget, fewer women may be served with fewer LYG. Changes in the program, such as only
including biennial screening, will increase LYG/screen and could offset the potential decrease in
LYG when shifting to digital mammography.
(Am J Prev Med 2015;48(5):535–542) & 2015 American Journal of Preventive Medicine. All rights reserved.
This is an open access article under the CC BY-NC-ND license
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van Ravesteyn et al / Am J Prev Med 2015;48(5):535–542536Early Detection Program (NBCCEDP). Started in 1991,
the program offers free or low-cost mammograms to
low-income, uninsured, and underinsured women aged
40–64 years. Speciﬁc eligibility criteria vary by state but
are generally limited to women with incomesr250% of
the federal poverty level, approximately 10% of all U.S.
women aged 40–64 years.4 In 2011, NBCCEDP screened
332,788 women for breast cancer with mammography
(11.7% of those eligible for screening within the
NBCCEDP),4 reaching a variety of race/ethnicity groups
(47% white, 24% Hispanic, 18% black, 5% Asian/Paciﬁc
Islander, and 6% other, multiracial, unknown).5 The
NBCCEDP supports biennial screening. However, some
women are screened annually when it is recommended
by their healthcare provider.
Following publication of the Digital Mammographic
Imaging Screening Trial (DMIST) in 2005,6 mammog-
raphy facilities gradually began shifting from plain-ﬁlm
to digital mammography, and by 2010, 47% of screening
examinations within the NBCCEDP were performed
using digital mammography. Digital mammography
has been found to have higher test sensitivity than plain
ﬁlm for women agedo50 years and women with dense
breasts.6 Overall, the diagnostic accuracy of digital and
ﬁlm mammography is similar, but digital screening is
more expensive than plain ﬁlm.6,7 This poses a potential
dilemma for the NBCCEDP, which operates based on a
ﬁxed appropriation. If the program were to cover the
higher costs of digital screening, it would not be able to
reach as many women as it could by paying for the less-
expensive plain-ﬁlm modality. However, if digital were to
perform better, then more lives might be saved. Thus, it is
unclear what the consequences of the transition from
ﬁlm to digital mammography would mean for the
number of averted breast cancer deaths and life-years
gained (LYG) through the program.
Two well-established microsimulation models were
used to estimate the impact of the transition from ﬁlm to
digital mammography among the target population of
the NBCCEDP in terms of program budget, numbers of
women served, numbers of averted breast cancer deaths,
and LYG. In addition, possibilities to increase the
efﬁciency of the program were evaluated (e.g., by only
including the most cost-effective screening scenarios).Methods
MIcrosimulation SCreening ANalysis—Fatal Diameter (MISCAN-
Fadia) and Simulating Population Effects of Cancer Control
inTerventions—Race and Understanding Mortality (SPECTRUM)
were used to assess the implications of shifting from ﬁlm to digital
mammography for the NBCCEDP. The models have been
developed independently within the Cancer Intervention andSurveillance Modeling Network (CISNET) and were exempt from
IRB approval. The models have previously been described in
detail8,9; information about the models can be found in the
Appendix (Appendix Figure 1) and online (cisnet.cancer.gov/
breast/proﬁles.html). Brieﬂy, the models simulated life histories
for individual women. After estimating breast cancer incidence
and mortality in the absence of screening and adjuvant therapy,
the models overlaid screening use and improvements in survival
associated with treatment advances.2,10–12
MISCAN-Fadia models continuous tumor growth, where tumors
can be detected once they are beyond a detection threshold and
cured if the tumor is below a fatal diameter.9 In SPECTRUM, tumors
progress through stages, with screening effects due to age and stage
shifts and adjuvant treatment reducing the hazard of death.8 In both
models, ductal carcinoma in situ is represented as a state that can
regress, remain, and be diagnosed or progress to invasive cancer.
A combination of primary data from 2010 from the NBCCEDP
and national data representative of the program’s target population
were used to develop common input parameters. In 2008, the
majority of women (89%) served by the NBCCEDP consisted of low-
income white, black, and Hispanic women.13 These groups were
modeled separately because the three groups have different disease
risk and characteristics.14 Model runs were performed in 2012.
A multicohort population matching the demographics of the
three racial/ethnic groups of women born between 1945 and 1970
(aged 40–64 years in 2010) was simulated. Each woman was
assigned a date of death due to causes other than breast cancer
based on race-speciﬁc data from the National Center for Health
Statistics.15 For Hispanic women, the non–breast cancer mortality
of white women was used because their life expectancy has been
found to be very similar.16 The simulated women die because of
breast cancer or of other causes, whichever comes ﬁrst.
The breast cancer incidence in the absence of screening was
based on an age–period–cohort model for the U.S. population.17
These data were applied for incidence rates for white women. Age-
speciﬁc relative risks for black versus white and Hispanic versus
white women from the Surveillance, Epidemiology, and End
Results (SEER) database were used to create age–period–cohort
data for each race/ethnic group.
SEER data for stage distribution and breast cancer–speciﬁc
survival for white and black women from 1975 to 1979 were used
to model the natural history of breast cancer in the absence of
mammography screening and adjuvant therapy, as these cancer
control interventions did not begin to disseminate into the pop-
ulation substantially until after 1980.10 SEER data for Hispanic
women speciﬁcally were only available from 1990 onwards. There-
fore, the stage distribution of clinical and interval cancers from the
Breast Cancer Surveillance Consortium (BCSC) were used to
estimate the stage distribution in the absence of screening for
Hispanic women (http://breastscreening.cancer.gov/). Breast can-
cer–speciﬁc survival of Hispanic women was assumed to be equal to
that of whites, when corrected for multiple factors (including age,
estrogen receptor [ER] status, and surgical treatment).18
Different screening behaviors as observed in the 2010 NBCCEDP
were used in the models by deﬁning annual screening (with an
interval of o18 months); biennial screening (18–30 months); and
screening irregularly or once (an interval of 430 months or no
previous screen within the NBCCEDP). The percentages of screens
performed annually, biennially, and irregularly varied somewhat by
age and by race/ethnicity group (Table 1).www.ajpmonline.org
Table 1. Main Model Parameters
Distribution of mammograms in the NBCCEDP
Screening interval Age group White, % Black, % Hispanic, % Total, %
Annual (o18 months) 40–49 6.2 1.5 3.1 10.9
50–64 18.7 6.3 5.6 30.6
Biennial (18–30 months) 40–49 2.0 0.6 1.3 3.9
50–64 2.9 1.4 1.4 5.7
Irregular/once 40–64 26.9 9.3 12.7 49.0
Total 56.8 19.0 24.1 100.0
Screening test performance: sensitivitya
Screening interval Age group Film Digital
Annual (o18 months) 40–49 0.74 0.76
50–64 0.78 0.81
Biennial (18–30 months) 40–49 0.80 0.82
50–64 0.84 0.85
Irregular/once 40–49 0.88 0.90
50–64 0.91 0.92
Screening test performance: speciﬁcity
Screening interval Age group Film Digital
Annual (o18 months) 40–49 0.91 0.89
50–64 0.92 0.91
Biennial (18–30 months) 40–49 0.90 0.87
50–64 0.91 0.89
Irregular/once 40–49 0.81 0.77
50–64 0.84 0.80
Cost of screening mammographyb Film Digital
$84 $115
Cost of diagnostic workupb Film Digital
True positive $1,842 $1,896
False positive $394 $443
aSensitivity based on a 12-month follow-up period for deﬁning interval cancers.
bCosts in 2010 U.S. dollars.
NBCCEDP, National Breast and Cervical Cancer Early Detection Program.
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performance in terms of sensitivity and speciﬁcity of ﬁlm and
digital mammography by age (40–49 and 50–64 years) and
screening interval (Table 1). Screening performance was assumed
to be equal for the three race/ethnicity groups.19 Treatment
effectiveness was age- and ER/human epidermal growth factor
receptor 2 (HER2)–speciﬁc and based on synthesis of recent
clinical trials.20–22 Treatment effects were modeled as a propor-
tionate reduction in mortality risk or the proportion cured.
Treatment use and treatment effects were modiﬁed for blacksMay 2015versus whites based on prior research.10 Treatment impact and use
for Hispanic women were assumed to be equal to those for
whites.18 Speciﬁc treatment data were available until 2005; there-
after, the same rates were assumed.
The most recent cost estimates were used for breast cancer
screening and follow-up diagnostics (Table 1). For the program
cost of screening, the weighted average NBCCEDP reimburse-
ment rates in 2009–2010 were used for ﬁlm and digital
mammography. For the cost of diagnostic workup, mean
workup costs within 12 months of initial screening of women
van Ravesteyn et al / Am J Prev Med 2015;48(5):535–542538with a true-positive and false-positive mammography interpre-
tation for digital and plain-ﬁlm evaluations were used.7 All costs
were updated to 2010 U.S. dollars, using the medical care
component of the Consumer Price Index (www.bls.gov/cpi/
data.htm).
Both models have previously been validated for black and white
women.10 For Hispanic women, model-projected age-adjusted
incidence and mortality were compared with actual SEER rates
available for 1992–2007 and 1990–2007, respectively. The costs
and health effects (LYG and breast cancer deaths averted) of the
screening scenarios performed within the NBCCEDP were esti-
mated by using the percentages of screens currently performed
annually, biennially, and irregularly or once in each age and race/
ethnicity group for ﬁlm mammography. In addition, the costs and
health effects of shifting to digital mammography assuming the
same screening distributions were assessed. Subsequently, the
health effects of the program using digital mammography were
estimated assuming a ﬁxed budget for the cost of screening and
diagnostics. Finally, the implications of only including the most
cost-effective digital screening scenarios in the NBCCEDP were
assessed. As biennial screening has been found to be more cost
effective than annual screening,23,24 the effect of only including
biennial digital screening was evaluated.
Multiple sensitivity analyses were performed to assess the
uncertainty around the costs and performance of digital mam-
mography using the upper and lower limit for the screening test
performance (sensitivity, speciﬁcity) and by assuming a 10%
lower cost for digital screening. The cost of diagnostics was alsoTable 2. Predicted Health Outcomes and Costs for the Differen
Race/
ethnicity Modality
Breast
cancer
deaths
averted Change LYG Cha
MISCAN-Fadia
White Film 0.32 5.9
White Digital 0.34 0.014 6.2 0.2
Black Film 0.46 8.0
Black Digital 0.48 0.018 8.3 0.3
Hispanics Film 0.21 4.0
Hispanics Digital 0.22 0.009 4.2 0.1
SPECTRUM
White Film 0.45 7.5
White Digital 0.45 0.007 7.6 0.1
Black Film 0.49 8.3
Black Digital 0.50 0.009 8.4 0.1
Hispanics Film 0.26 4.5
Hispanics Digital 0.26 0.005 4.6 0.0
aCosts rounded to nearest 1,000.
LYG, life-years gained; MISCAN-Fadia, MIcrosimulation SCreening Analysis—
Control inTerventions—Race and Understanding Mortality.varied, as previous work showed that the increase in follow-up
costs associated with digital mammography diminished over
time.25Results
The age-adjusted incidence and mortality rates of both
models have been previously published for black and
white women.10 For Hispanic women, the predicted age-
adjusted incidence and mortality rates of both models
were close to the observed SEER rates (Appendix Figures
2 and 3). The health effects of screening varied by race/
ethnicity: the models predicted 8.0–8.3 (range across
models) LYG per 1,000 ﬁlm screens for black women,
5.9–7.5 for white women, and 4.0–4.5 for Hispanic
women. The absolute change in LYG when the 1,000
screens were performed digitally was rather small and
also varied by race/ethnicity and model (0.089–0.316)
(Table 2). The number of false-positives and costs per
1,000 screens did not vary substantially by race/ethnicity,
and both increased considerably with digital mammog-
raphy. Per 1,000 screens, the number of false-positives
increased by 24–28 and the costs increased by $47,000–
$51,000 (Table 2).t Race/Ethnicity Groups per 1,000 Mammograms
nge
False-
positives Change
Costs (screen
and
diagnostics),a
$
Change,
$
112 137,000
76 136 25 185,000 47,000
112 136,000
16 136 24 183,000 47,000
122 137,000
78 148 26 186,000 49,000
128 149,000
22 155 27 199,000 50,000
126 148,000
56 153 27 198,000 50,000
133 146,000
89 162 28 196,000 51,000
Fatal Diameter; SPECTRUM, Simulating Population Effects of Cancer
www.ajpmonline.org
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using ﬁlm mammography, the 329,721 mammograms
that were performed in 2010 would avert 107–136 breast
cancer deaths with 1,948–2,305 LYG. If the same number
of mammograms were performed digitally, there would
be 111–138 breast cancer deaths averted and 2,034–2,345
LYG, a 2%–4% increase (Table 3). At the same time, the
program costs would increase 34%–35%. Assuming level
funding and a transition to entirely digital screening,
25%–26% fewer women could be served with digital than
with ﬁlm mammography. This would result in fewer
breast cancer deaths averted (23%–24%) and LYG (22%–
24%) (Table 3).
When only including biennial digital screening, still
fewer women would be served, but the beneﬁt per screen
was higher for biennial than for annual screening.Table 3. Implications of Switching from Film to Digital Mammo
Modality
Distribution
of mmg Assumptions
Number of mmg
(% change)a
MISCAN-Fadia
Film As observed
within the
NBCCEDPb
Fixed no. of
mmg
329,721
Digital As observed
within the
NBCCEDPb
Fixed no. of
mmg
329,721
Digital As observed
within the
NBCCEDPb
Fixed budget 244,723 (–25.8%
Digital Biennialc Fixed budget 277,257 (–15.9%
Digital Biennialc age
Z50
Fixed budget 282,474 (–14.3%
SPECTRUM
Film As observed
within the
NBCCEDPb
Fixed no. of
mmg
329,721
Digital As observed
within the
NBCCEDPb
Fixed no. of
mmg
329,721
Digital As observed
within the
NBCCEDPb
Fixed budget 246,020 (–25.4%
Digital Biennialc Fixed budget 275,113 (–16.6%
Digital Biennialc age
Z50
Fixed budget 273,420 (–17.1%
aCompared to ﬁlm mammography.
bSee Table 1.
cScreening interval 18–30 months.
BC, breast cancer; LYG, life-years gained; MISCAN-Fadia, MIcrosimulation
National Breast and Cervical Cancer Early Detection Program; SPECTRUM, S
Understanding Mortality.
May 2015Restricting the screening interval to biennial therefore
leads to a higher number of LYG per screen. When a
ﬁxed budget was assumed, the change in LYG inversed
from a loss of 22%–24% to an increase of 8%–13%
(Table 3). Moreover, if biennial screening were restricted
to women aged Z50 years, the number of LYG would
increase by 16%–17%.
Varying the screening test performance of digital mam-
mography did not change the results substantially; when
including the upper limit of the screening test sensitivity,
LYG and breast cancer deaths averted only slightly increased
(o2%). When a 10% lower cost for digital screening was
assumed, the total cost of screening and diagnostics
increased by 26% (both models) instead of 34%–35%. Total
costs increased by 29%–30% when assuming the same cost
of diagnostics for digital as for ﬁlm mammography.graphy in the NBCCEDP
LYG (%
change)a
BC deaths
averted (%
change)a
Costs screen and
diagnostics (million $)
(% change)a
1,948 107 $45.2
2,034 (4.4%) 111 (4.2%) $60.9 (34.7%)
) 1,510 (–22.5%) 83 (–22.6%) $45.2
) 2,196 (12.8%) 116 (8.9%) $45.2
) 2,257 (15.9%) 135 (26.1%) $45.2
2,305 136 $48.8
2,345 (1.7%) 138 (1.7%) $65.4 (34.0%)
) 1,749 (–24.1%) 103 (–24.1%) $48.8
) 2,481 (7.7%) 141 (3.6%) $48.8
) 2,693 (16.8%) 169 (24.0%) $48.8
SCreening ANalysis—Fatal Diameter; mmg, mammograms; NBCCEDP,
imulating Population Effects of Cancer Control inTerventions—Race and
Prev Med 2015;48(5):535–542Discussion
Digital mammography could result in slightly more LYG
than ﬁlm mammography within the NBCCEDP. How-
ever, with a ﬁxed budget, fewer women may be served
with fewer LYG, because a lower number of screening
tests can be funded. Digital mammography is more
costly, mainly because of the higher cost of the screening
test and higher cost due to more false-positives. When
performing the same number of mammograms in the
NBCCEDP using digital mammography, program costs
would increase by 34%–35%. Changes in the program,
such as only including biennial screening, will lead to
more LYG per screen and could thereby offset the
potential decrease in LYG when shifting to digital
mammography. However, for a subset of women who
switch from annual to biennial screening, their cancers
will be detected at a later, more advanced stage.
Assuming continued level funding, there are several ways
that the NBCCEDP might maintain its reach and achieve
comparable health effects (LYG and breast cancer deaths
averted) of ﬁlm and digital mammography. The ﬁrst way
would be a price reduction of digital mammography (or a
change in reimbursement fee). In California’s Every
Woman Counts program, digital mammography was
reimbursed at the same rate as ﬁlm mammography.23
However, this has recently been changed and is not easily
achievable for the NBCCEDP. The second way is to
implement program changes and only provide screening
with a biennial interval. In this case, the number of LYG can
even be increased. Another option is to only include women
agedZ50 years. However, the effect of this change is quite
small, as only 15% of the NBCCEDP mammograms are
performed on women aged o50 years. In addition to the
options that were investigated, there might be other
program changes that would potentially be even more cost
effective (e.g., screening with even longer intervals or
focusing on high-risk groups). As the NBCCEDP is
concerned with providing screening services based on the
best evidence, the present study focused on scenarios that
were in line with current U.S. Preventive Services Task
Force breast cancer screening recommendations.26
The implementation of mandatory coverage for breast
cancer screening under the Affordable Care Act may
reduce the demand for the NBCCEDP. Currently,
NBCCEDP is projected to reach around 11.7% of those
eligible, and in the near future, the number eligible will
likely still exceed the number served. However, previous
work projected changes in the population characteristics
of the eligible population, including a larger percentage of
Asians and Hispanics.27
An important strength of this study is that an
ethnically diverse population was included by speciﬁcally
modeling white, black, and Hispanic women. As these
van Ravesteyn et al / Am J540racial/ethnic groups have been found to have different
risks of getting and dying from breast cancer,28 it is
essential to speciﬁcally incorporate these differences to
adequately reﬂect the women served by the NBCCEDP,
as highlighted by the ﬁnding that the impact of the
transition to digital mammography varied by race/
ethnicity. In addition, two models were used to provide
a range of plausible effects and illustrate the effects of
differences in model structure. Furthermore, recent data
on screening performance were used from the BCSC
because previous work found that results from BCSC and
NBCCEDP were broadly similar.29 An advantage is that
data from BCSC reﬂect screening performance in com-
munity practice, which might be different from the
performance in screening trials.
Despite these strengths and the consistent results, this
study has some limitations. First, it was assumed that
women in the NBCCEDP received the same treatment
as women in the overall U.S. population. Although low-
income, uninsured women might not always receive
optimal treatment,30 women diagnosed through the
NBCCEDP are enrolled in Medicaid for treatment,
and it has been found that almost 94% of women
initiated treatment within 60 days after diagnosis.31
Second, it was not feasible to include other minority
groups, including Asian/Paciﬁc Islanders, other/
unknown, and multiracial women, because of the
limited available data for these groups. Together, these
latter groups comprise 11% of NBCCEDP’s population.
Adding these other minority groups would probably not
have substantially inﬂuenced the ﬁndings, although
Asian women more often have dense breasts,32 and
for women with dense breasts, digital mammography
might be more cost effective. Finally, it has been found
that the performance of digital mammography may
improve and costs may decrease over time.25,33,34 A
recent study25 found that the increase in downstream
breast-related cost (follow-up services related to diag-
nostic workup) associated with digital mammography
diminished over time. In the sensitivity analysis, when
assuming the same cost of diagnostics for digital as for
ﬁlm, maintaining current screening levels would
increase the cost to the program by 29%–30% instead
of 34%–35%.
In conclusion, although digital could result in slightly
more LYG than ﬁlm mammography, fewer women can
be served by the NBCCEDP with shifting from ﬁlm to
digital mammography, thus leading to fewer LYG. As
mammography facilities have switched to using digital
mammography, it is important for program administra-
tors and decision-makers at the state and federal level to
understand the health beneﬁt and cost impact related to
using digital versus ﬁlm mammography.www.ajpmonline.org
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